Resources

 Inodiab study: improvement of type 2 diabetes patients’ adherence

To access the SPUR™ research website, click here.

Inodiab is the first French randomized study on the effects of a personalized SMS patient engagement program piloted by pharmacists.

It demonstrates a positive and significant impact on the adherence of type 2 diabetic patients (T2D) as well as on their Body Mass Index (BMI).

 

The infographic:

bandeau ino en

 

Presentation of the results: 

An increase in the MMAS-8 score (indicator of adherence) of patients in the SMS group was observed between the time intervals 0 and 1 month and 0 and 3 months and was significantly higher than in the control group. 

Among the biological data measured, body mass index decreased significantly in the group of patients receiving the messages compared to the control group between 0 and 3 months. This benefit was not observed between 0 and 6 months. HDL cholesterol, glycated hemoglobin, and physical activity (measured by the International Physical Activity Questionnaire IPAQ-SF) did not show significant differences between the two study groups.

The personalization of this SMS support service, made possible by a detailed analysis of individual behavioral levers, coupled with the intervention of pharmacistsled to a significant improvement in patients' medical adherence and physical condition (BMI). 

Access the scientific publication

Please fill in the form to download the infographic :

inodiab.png

 

 

Share

See also

Scientific communications

A multiple-cohort analysis of the SPUR 6/24 patient-reported adherence tool

Articles

Clinical Ink and Observia: Pioneering Personalized Patient Engagement in Clinical Trials

News

By your side in 2024: Happy Holidays from Observia!

Accès plateformes